Sugi Predict

Sugi Predict / Targets / FLT1

FLT1

Vascular endothelial growth factor receptor 1 · P17948 · FLT1 on Sugi Atlas →

198,815 patent compounds predicted against FLT1, 138,870 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vatalanib Vatalanib (SCHEMBL18286) 1.00 19/20
SCHEMBL95010 SCHEMBL95010 0.81 18/20
Vandetanib Vandetanib (SCHEMBL9044) 1.00 11/20
SCHEMBL9280 SCHEMBL9280 0.77 11/20
Linifanib Linifanib (SCHEMBL93804) 1.00 9/20
SCHEMBL58313 SCHEMBL58313 0.59 8/20
SCHEMBL66159 SCHEMBL66159 0.49 8/20
SCHEMBL60289 SCHEMBL60289 0.48 8/20
SCHEMBL60366 SCHEMBL60366 0.47 8/20
SCHEMBL58735 SCHEMBL58735 0.47 8/20
SCHEMBL58496 SCHEMBL58496 0.44 8/20
SCHEMBL11517 SCHEMBL11517 0.84 7/20
SCHEMBL58543 SCHEMBL58543 0.57 7/20
SCHEMBL60464 SCHEMBL60464 0.57 7/20
SCHEMBL59547 SCHEMBL59547 0.49 7/20
SCHEMBL90887 SCHEMBL90887 0.49 7/20
SCHEMBL90935 SCHEMBL90935 0.49 7/20
SCHEMBL59726 SCHEMBL59726 0.42 7/20
SCHEMBL58550 SCHEMBL58550 0.55 6/20
SCHEMBL57834 SCHEMBL57834 0.55 6/20

Clinical trials — most relevant to FLT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma PHASE3COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment PHASE2COMPLETED
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers PHASE1/PHASE2COMPLETED
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites PHASE1/PHASE2RECRUITING
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma PHASE2COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment PHASE2UNKNOWN
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors PHASE1COMPLETED
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) PHASE1COMPLETED
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial nanUNKNOWN
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED
Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia nanCOMPLETED
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler nanNOT_YET_RECRUITING
sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19? nanCOMPLETED
Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia nanCOMPLETED
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis nanUNKNOWN
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α. nanUNKNOWN
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece nanCOMPLETED
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib nanCOMPLETED
Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FLT1 binder may also engage these)

ProteinNameSimilarity
P53767 — 1.000 P53767 →
Q8QHL3 — 1.000 Q8QHL3 →
P35969 — 1.000 P35969 →
P52583 — 0.998 P52583 →
Q5GIT4 — 0.996 Q5GIT4 →
Q7T2H2 — 0.995 Q7T2H2 →
P79701 — 0.994 P79701 →
KDR Vascular endothelial growth factor receptor 2 0.994 landscape →
Q5MD89 — 0.994 Q5MD89 →
Q00495 — 0.993 Q00495 →
Q8JFR5 — 0.992 Q8JFR5 →
P35917 — 0.992 P35917 →
P26619 — 0.992 P26619 →
Q91ZT1 — 0.992 Q91ZT1 →
Q9I8N6 — 0.991 Q9I8N6 →
O08775 — 0.991 O08775 →
P35918 — 0.991 P35918 →
P60029 — 0.991 P60029 →
Q8AXB3 — 0.990 Q8AXB3 →
Q8AXC7 — 0.990 Q8AXC7 →
B0CLX4 — 0.990 B0CLX4 →
O95185 — 0.990 O95185 →
P43481 — 0.990 P43481 →
Q7YQL9 — 0.990 Q7YQL9 →
Q28889 — 0.990 Q28889 →
Q5VJ70 — 0.989 Q5VJ70 →
Q62611 — 0.989 Q62611 →
Q9PUF6 — 0.989 Q9PUF6 →
P59823 — 0.989 P59823 →
Q9ERS6 — 0.989 Q9ERS6 →